| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 0.00 | — |
| Operating expense | — | — |
| Net income | -17.96M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, CRVS returned +160.5% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +87.8% |
| 1 year | +160.5% |
| 5 years | +539.8% |
| 10 years | +5.9% |
| All-time high | $20.77 (Mar 2017) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in CRVS would be worth today ›No. Corvus Pharmaceuticals, Inc. has not paid a dividend in the past 12 months.
Corvus Pharmaceuticals, Inc. stock trades on NASDAQ under the ticker symbol CRVS.
Corvus Pharmaceuticals, Inc. is part of the Healthcare sector.
Corvus Pharmaceuticals, Inc. has a market cap of 1.22B USD, based on the latest quote.
Corvus Pharmaceuticals, Inc. is expected to report earnings around Nov 3, 2026. That date is an estimate and has not been confirmed by the company.
